<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20250207</date><key>collection.key</key><document><id>PMC5514105</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.1038/s41598-017-06101-6</infon><infon key="article-id_pmc">PMC5514105</infon><infon key="article-id_pmid">28717233</infon><infon key="article-id_publisher-id">6101</infon><infon key="elocation-id">5596</infon><infon key="license">
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleâs Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleâs Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.</infon><infon key="name_0">surname:Climent;given-names:Elisenda</infon><infon key="name_1">surname:PÃ©rez-Calahorra;given-names:SofÃ­a</infon><infon key="name_10">surname:Civeira;given-names:Fernando</infon><infon key="name_11">surname:Pedro-Botet;given-names:Juan</infon><infon key="name_2">surname:Marco-BenedÃ­;given-names:Victoria</infon><infon key="name_3">surname:Plana;given-names:Nuria</infon><infon key="name_4">surname:SÃ¡nchez;given-names:Rosa</infon><infon key="name_5">surname:Ros;given-names:Emilio</infon><infon key="name_6">surname:Ascaso;given-names:Juan F.</infon><infon key="name_7">surname:Puzo;given-names:Jose</infon><infon key="name_8">surname:Almagro;given-names:FÃ¡tima</infon><infon key="name_9">surname:Lahoz;given-names:Carlos</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">7</infon><infon key="year">2017</infon><offset>0</offset><text>Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>144</offset><text>Patients with heterozygous familial hypercholesterolemia (HeFH) have been reported to be less vulnerable to type 2 diabetes mellitus (T2DM), although the mechanism is unknown. The aims of the present study were to assess the effects of low density lipoprotein (LDL) cholesterol concentration and the presence of FH-causing mutations on T2DM prevalence in HeFH. Data were collected from the Dyslipidemia Registry of the Spanish Arteriosclerosis Society. Inclusion criteria were definite or probable HeFH in patients aged â¥18 years. T2DM prevalence in HeFH patients was compared with data of the general population. 1732 patients were included. The prevalence of T2DM was lower in patients with HeFH compared with the general population (5.94% vs 9.44%; OR: 0.606, 95% CI 0.486â0.755, pâ&lt;â0.001). Risk factors for developing T2DM were male sex, age, body mass index, hypertension, baseline triglyceride levels and years on statin therapy. The prevalence of T2DM in HeFH patients was 40% lower than that observed in the general population. Gene mutations and LDL cholesterol concentrations were not risk factors associated with the prevalence of T2DM in patients with HeFH. The prevalence of T2DM in patients with HeFH was 40% lower than in the general population matched for age and sex.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1438</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1451</offset><text>Heterozygous familial hypercholesterolemia (HeFH), the most frequent monogenic disorder of human metabolism caused by some mutations in the genes that encode for the low-density lipoprotein (LDL) receptor, apolipoprotein (apo) B, proprotein convertase subtilisin/kexin-type 9 (PCSK9) or apo E, entails an increased risk of premature cardiovascular disease.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1808</offset><text>Patients with HeFH had been reported to be less vulnerable to type 2 diabetes mellitus (T2DM) compared to the general population. More recently, Besseling et al. in a cross-sectional study found the prevalence of T2DM to be 50% lower in HeFH patients compared to unaffected relatives. One of the mechanisms suggested to explain this finding lies in potential decreased cholesterol uptake by pancreatic Î² cells in HeFH. This lower T2DM risk contrasts with the fact that most HeFH patients are treated with high doses of potent statins which exert a dose-dependent diabetogenic effect. The molecular pathways that may be involved in the resistance to T2DM in HeFH and the statin-related T2DM have not been studied in depth in humans. Suggested mechanisms include defects in insulin signaling, pancreatic Î² -cell function and reduced glucose uptake in adipocytes throughout the glucose transporter-4 (GLUT4) pathway. The potential effect of LDLR mutations or LDL cholesterol concentration on these anti-diabetogenic and pro-diabetogenic effects of HeFH and statins, respectively, are unknown.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2904</offset><text>The cholesterol-lowering effect of statin therapy is mainly due to the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme in cholesterol synthesis that induces a reduction in intracellular cholesterol content and a subsequent increase in LDL receptor expression in different tissues and the promotion of transmembrane cholesterol transport, the primary altered mechanism in FH. If intracellular cholesterol uptake via the LDL receptor is involved in the pathogenesis of T2DM, then it would explain the hypothetical protection from diabetes in HeFH patients, but only in those with genetic defects affecting LDL receptor uptake, in contrast to the hypothesis that the protection would be dependent on the high plasma LDL-cholesterol concentrations observed in HeFH. Hence, the aims of the present study were to assess the prevalence of T2DM in HeFH patients of the Dyslipidemia Registry of the Spanish Arteriosclerosis Society, and evaluate the impact of mutations in the LDLR, APOB and PCSK9 genes, baseline LDL cholesterol concentration and duration of statin treatment on T2DM prevalence in this population.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4032</offset><text>Research Design and Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4060</offset><text>Study population</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4077</offset><text>The Dyslipidemia Registry of the Spanish Arteriosclerosis Society was created at the end of 2013 as an active on-line registry in which 50 certified Lipid Units distributed throughout Spain enter cases with different primary hyperlipidemias. These Lipid Units are the centers in the Spanish National Health Service to which most cases of primary hyperlipidemias are referred for diagnosis and treatment. The registry was approved by a central ethics committee to include anonymous clinical data (ComitÃ© Ãtico de InvestigaciÃ³n ClÃ­nica de AragÃ³n, Zaragoza, Spain) in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Patients did not have to complete an informed consent form as the data were obtained from an official national registry. Minimum data for the inclusion of cases in the registry are: age, sex, smoking status, personal history of hypertension, diabetes and cardiovascular disease with age at the first event, body mass index (BMI), waist circumference, total cholesterol, LDL cholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol without lipid-lowering treatment, and clinical diagnosis. Cardiovascular disease in the registry is defined as: coronary heart disease (myocardial infarction, acute coronary syndrome with stenosis &gt;50% of a main coronary artery and coronary revascularization), stroke (ischemic and hemorrhagic), aortic aneurysm and lower limb ischemia (intermittent claudication with ankle/brachial index &lt;0.90 or revascularization of lower limb arteries). T2DM is defined in the presence of fasting blood glucose &gt;125âmg/dL or use of blood glucose-lowering drugs.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5722</offset><text>Inclusion criteria in the present study were: complete minimum data for the registry, plus information on family history of hypercholesterolemia and premature cardiovascular disease; personal history of tendon xanthomas and presence of arcus cornealis before the age of 45; genetic study of LDLR, APOB and PCSK9 genes; age at statin onset; and age at T2DM diagnosis. Only subjects with probable (6â8 points) or definite (&gt;8 points) HeFH according to the Dutch Lipid Clinic Network criteria and age â¥18 years were finally included. The diagnosis of homozygous FH (HoFH) was an exclusion criterion.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6323</offset><text>Of the 2,475 cases with the clinical diagnosis of genetic hypercholesterolemia included in the registry, 1,732 diagnosed of HeFH with Dutch Lipid Clinic Network (DLCN) criteria â¥6 points and complete data were finally included. Reasons for exclusion from the analysis were HoFH or DLCN &lt;6 points and lack of data on genetic analysis, among others.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6673</offset><text>The prevalence of T2DM was analyzed according to a probable or definite diagnosis of HeFH, the presence of a genetic mutation or the gene involved. Furthermore, T2DM prevalence in HeFH patients was compared with data of the general population matched for age and sex from the Di@bet.es Study. The Di@bet.es Study is a national, cross-sectional, population-based survey conducted in 2009â10 in a representative random sample of the Spanish population.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7126</offset><text>Blood specimens were collected after an overnight (&gt;10âh) fast and processed for laboratory analyses the same day. Serum total cholesterol, triglycerides and HDL cholesterol levels were measured locally using enzymatic methods. Serum LDL cholesterol concentration was calculated using the Friedewald formula.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7437</offset><text>DNA was isolated from whole blood using standard methods and screening for LDLR, APOB and PCSK9 mutations was carried out using the Lipochip Platform (Progenika Biopharma S. A., Bilbao, Spain). The platform consists of two consecutive steps: the first is LIPOchipÂ® microarray analysis for the detection of the most frequent Spanish point mutations in the LDLR gene and in the APOB exon 26, as well as CNVs in LDLR. When the LIPOchipÂ® microarray yielded a negative result (no mutation is found), the LDLR, APOB (binding domain) and PCSK9 gene coding sequences, exon-intron boundaries, and short proximal intronic sequences were sequenced with a GS Junior system (Roche Diagnostics Corporation, Basel, Switzerland).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8153</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8174</offset><text>Data were expressed as meanâÂ±âstandard deviation for parametric variables and as medianâÂ±âinterquartile range for non-parametric quantitative variables. The Mann-Whitney U test was used for comparison between groups; quantitative variables were shown as % (n) and chi-square test was applied for qualitative variables between groups. Logistic regression analysis including sex, age, BMI, smoking status, hypertension, tendon xanthomas, baseline LDL and HDL cholesterol and triglyceride concentrations, genetic diagnosis and statin therapy duration was applied to evaluate factors independently associated with the presence of T2DM in HeFH patients. A two-sided p valueâ&lt;â0.05 was considered statistically significant. Statistical analysis was calculated with SPSS (version 19.0 for Windows; SPSS, Chicago, IL).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>8999</offset><text>Results</text></passage><passage><infon key="file">41598_2017_6101_Fig1_HTML.jpg</infon><infon key="id">Fig1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>9007</offset><text>Study flow diagram. HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; DLCN, Dutch Lipid Clinic Network.</text></passage><passage><infon key="file">Tab1.xml</infon><infon key="id">Tab1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>9159</offset><text>Demographic and clinical characteristics of heterozygous familial hypercholesterolemia patients.</text></passage><passage><infon key="file">Tab1.xml</infon><infon key="id">Tab1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Characteristics&lt;/th&gt;&lt;th&gt;Probable FH Nâ=â354&lt;/th&gt;&lt;th&gt;Definite FH Nâ=â1,378&lt;/th&gt;&lt;th&gt;
&lt;italic&gt;P&lt;/italic&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Men, % (n)&lt;/td&gt;&lt;td&gt;50.0 (177)&lt;/td&gt;&lt;td&gt;48.9 (674)&lt;/td&gt;&lt;td&gt;0.715&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Age, years&lt;/td&gt;&lt;td&gt;56.0 (49.0â64.5)&lt;/td&gt;&lt;td&gt;50.0 (38.0â60.0)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Body mass index, kg/m&lt;sup&gt;2&lt;/sup&gt;
&lt;/td&gt;&lt;td&gt;26.7 (22.5â28.6)&lt;/td&gt;&lt;td&gt;26.2 (24.0â28.9)&lt;/td&gt;&lt;td&gt;0.006&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Waist circumference, cm&lt;/td&gt;&lt;td&gt;93.0 (84.5â99.0)&lt;/td&gt;&lt;td&gt;90.0 (78.0â97.0)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Total cholesterol, mg/dL&lt;/td&gt;&lt;td&gt;300 (272â333)&lt;/td&gt;&lt;td&gt;340 (298â395)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Triglycerides, mg/dL&lt;/td&gt;&lt;td&gt;143 (99.5â194)&lt;/td&gt;&lt;td&gt;105 (75.0â143)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HDL cholesterol, mg/dL&lt;/td&gt;&lt;td&gt;54.0 (46.5â64.5)&lt;/td&gt;&lt;td&gt;53.0 (44.0â64.0)&lt;/td&gt;&lt;td&gt;0.753&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;LDL cholesterol, mg/dL&lt;/td&gt;&lt;td&gt;213 (190â251)&lt;/td&gt;&lt;td&gt;260 (216â316)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Glucose, mg/dL&lt;/td&gt;&lt;td&gt;91.0 (84.5â97.5)&lt;/td&gt;&lt;td&gt;89.0 (81.0â98.0)&lt;/td&gt;&lt;td&gt;0.051&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Tendon xanthomas, % (n)&lt;/td&gt;&lt;td&gt;3.3 (12)&lt;/td&gt;&lt;td&gt;35.2 (485)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Cardiovascular disease, % (n)&lt;/td&gt;&lt;td&gt;11.9 (42)&lt;/td&gt;&lt;td&gt;13.4 (185)&lt;/td&gt;&lt;td&gt;0.489&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hypertension, % (n)&lt;/td&gt;&lt;td&gt;26.4 (93)&lt;/td&gt;&lt;td&gt;17.7 (244)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Diabetes, % (n)&lt;/td&gt;&lt;td&gt;9.1 (32)&lt;/td&gt;&lt;td&gt;5.2 (71)&lt;/td&gt;&lt;td&gt;0.006&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Age at diabetes diagnosis, years&lt;/td&gt;&lt;td&gt;54.0 (50.8â60.0)&lt;/td&gt;&lt;td&gt;52.5 (46.5â60.3)&lt;/td&gt;&lt;td&gt;0.563&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Age at statin onset, years&lt;/td&gt;&lt;td&gt;48.3 (37.0â56.0)&lt;/td&gt;&lt;td&gt;41.0 (31.0â51.0)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Statin therapy, years&lt;/td&gt;&lt;td&gt;5.0 (2.0â11.0)&lt;/td&gt;&lt;td&gt;7.0 (3.0â13.0)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>9256</offset><text>Characteristics	Probable FH Nâ=â354	Definite FH Nâ=â1,378	P	 	Men, % (n)	50.0 (177)	48.9 (674)	0.715	 	Age, years	56.0 (49.0â64.5)	50.0 (38.0â60.0)	&lt;0.001	 	Body mass index, kg/m2	26.7 (22.5â28.6)	26.2 (24.0â28.9)	0.006	 	Waist circumference, cm	93.0 (84.5â99.0)	90.0 (78.0â97.0)	&lt;0.001	 	Total cholesterol, mg/dL	300 (272â333)	340 (298â395)	&lt;0.001	 	Triglycerides, mg/dL	143 (99.5â194)	105 (75.0â143)	&lt;0.001	 	HDL cholesterol, mg/dL	54.0 (46.5â64.5)	53.0 (44.0â64.0)	0.753	 	LDL cholesterol, mg/dL	213 (190â251)	260 (216â316)	&lt;0.001	 	Glucose, mg/dL	91.0 (84.5â97.5)	89.0 (81.0â98.0)	0.051	 	Tendon xanthomas, % (n)	3.3 (12)	35.2 (485)	&lt;0.001	 	Cardiovascular disease, % (n)	11.9 (42)	13.4 (185)	0.489	 	Hypertension, % (n)	26.4 (93)	17.7 (244)	&lt;0.001	 	Diabetes, % (n)	9.1 (32)	5.2 (71)	0.006	 	Age at diabetes diagnosis, years	54.0 (50.8â60.0)	52.5 (46.5â60.3)	0.563	 	Age at statin onset, years	48.3 (37.0â56.0)	41.0 (31.0â51.0)	&lt;0.001	 	Statin therapy, years	5.0 (2.0â11.0)	7.0 (3.0â13.0)	&lt;0.001	 	</text></passage><passage><infon key="file">Tab1.xml</infon><infon key="id">Tab1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>10312</offset><text>Values are expressed as median (interquartile range) for continuous variables and percentage (n) for categorical variables.</text></passage><passage><infon key="file">Tab1.xml</infon><infon key="id">Tab1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>10436</offset><text>HDL denotes high-density lipoprotein; LDL, low-density lipoprotein.</text></passage><passage><infon key="file">Tab2.xml</infon><infon key="id">Tab2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>10504</offset><text>Demographic and clinical characteristics of heterozygous familial hypercholesterolemia patients with or without diabetes.</text></passage><passage><infon key="file">Tab2.xml</infon><infon key="id">Tab2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Characteristics&lt;/th&gt;&lt;th&gt;Diabetes Nâ=â103&lt;/th&gt;&lt;th&gt;No diabetes Nâ=â1,629&lt;/th&gt;&lt;th&gt;
&lt;italic&gt;P&lt;/italic&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Men, % (n)&lt;/td&gt;&lt;td&gt;58.3 (60)&lt;/td&gt;&lt;td&gt;48.6 (792)&lt;/td&gt;&lt;td&gt;0.057&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Age, years&lt;/td&gt;&lt;td&gt;64 (55.0â69.0)&lt;/td&gt;&lt;td&gt;51.0 (40.0â60.0)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Body mass index, kg/m&lt;sup&gt;2&lt;/sup&gt;
&lt;/td&gt;&lt;td&gt;28.9 (25.3â33.3)&lt;/td&gt;&lt;td&gt;25.5 (22.8â28.4)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Waist circumference, cm&lt;/td&gt;&lt;td&gt;100 (92.0â108)&lt;/td&gt;&lt;td&gt;89.0 (80.0â96.0)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Total cholesterol, mg/dL&lt;/td&gt;&lt;td&gt;348 (291â395)&lt;/td&gt;&lt;td&gt;331 (292â384)&lt;/td&gt;&lt;td&gt;0.318&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Triglycerides, mg/dL&lt;/td&gt;&lt;td&gt;189 (129â256)&lt;/td&gt;&lt;td&gt;106 (78.0â155)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HDL cholesterol, mg/dL&lt;/td&gt;&lt;td&gt;47.5 (35.0â59.0)&lt;/td&gt;&lt;td&gt;53.0 (45.0â64.0)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;LDL cholesterol, mg/dL&lt;/td&gt;&lt;td&gt;255 (202â312)&lt;/td&gt;&lt;td&gt;253 (211â300)&lt;/td&gt;&lt;td&gt;0.960&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HbA1c*, %&lt;/td&gt;&lt;td&gt;6.7 (6.2â7.4)&lt;/td&gt;&lt;td&gt;5.5 (5.3â5.9)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Tendon xanthomas, % (n)&lt;/td&gt;&lt;td&gt;32.0 (33)&lt;/td&gt;&lt;td&gt;28.7 (468)&lt;/td&gt;&lt;td&gt;0.487&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Positive genetic diagnosis, % (n)&lt;/td&gt;&lt;td&gt;46.6 (48)&lt;/td&gt;&lt;td&gt;64.6 (1052)&lt;/td&gt;&lt;td&gt;0.005&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Cardiovascular disease, % (n)&lt;/td&gt;&lt;td&gt;40.8 (42)&lt;/td&gt;&lt;td&gt;11.3 (184)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hypertension, % (n)&lt;/td&gt;&lt;td&gt;64.1 (66)&lt;/td&gt;&lt;td&gt;16.7 (271)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Age at diabetes diagnosis, years&lt;/td&gt;&lt;td&gt;53.0 (48.0â60â0)&lt;/td&gt;&lt;td/&gt;&lt;td&gt;â&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Age at statin onset, years&lt;/td&gt;&lt;td&gt;51.5 (43.0â59.0)&lt;/td&gt;&lt;td&gt;42.0 (31.5â52.0)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Statin therapy, years&lt;/td&gt;&lt;td&gt;10.0 (6.0â17.0)&lt;/td&gt;&lt;td&gt;7.0 (2.5â12.0)&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>10626</offset><text>Characteristics	Diabetes Nâ=â103	No diabetes Nâ=â1,629	P	 	Men, % (n)	58.3 (60)	48.6 (792)	0.057	 	Age, years	64 (55.0â69.0)	51.0 (40.0â60.0)	&lt;0.001	 	Body mass index, kg/m2	28.9 (25.3â33.3)	25.5 (22.8â28.4)	&lt;0.001	 	Waist circumference, cm	100 (92.0â108)	89.0 (80.0â96.0)	&lt;0.001	 	Total cholesterol, mg/dL	348 (291â395)	331 (292â384)	0.318	 	Triglycerides, mg/dL	189 (129â256)	106 (78.0â155)	&lt;0.001	 	HDL cholesterol, mg/dL	47.5 (35.0â59.0)	53.0 (45.0â64.0)	&lt;0.001	 	LDL cholesterol, mg/dL	255 (202â312)	253 (211â300)	0.960	 	HbA1c*, %	6.7 (6.2â7.4)	5.5 (5.3â5.9)	&lt;0.001	 	Tendon xanthomas, % (n)	32.0 (33)	28.7 (468)	0.487	 	Positive genetic diagnosis, % (n)	46.6 (48)	64.6 (1052)	0.005	 	Cardiovascular disease, % (n)	40.8 (42)	11.3 (184)	&lt;0.001	 	Hypertension, % (n)	64.1 (66)	16.7 (271)	&lt;0.001	 	Age at diabetes diagnosis, years	53.0 (48.0â60â0)		â	 	Age at statin onset, years	51.5 (43.0â59.0)	42.0 (31.5â52.0)	&lt;0.001	 	Statin therapy, years	10.0 (6.0â17.0)	7.0 (2.5â12.0)	&lt;0.001	 	</text></passage><passage><infon key="file">Tab2.xml</infon><infon key="id">Tab2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>11669</offset><text>*Values refer to 87 (84.5%) diabetics and 410 (25.2%) non-diabetics.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11738</offset><text>One thousand, seven hundred and thirty-two patients were included (354 with probable and 1,378 with definite HeFH) (Fig.Â 1). No differences were found between groups in terms of gender, cardiovascular disease prevalence and HDL cholesterol concentration. As expected because of the DLCN definition, total cholesterol and LDL cholesterol concentrations were higher, and the presence of tendon xanthomas more common in definite than in probable HeFH. In contrast, the prevalence of T2DM and variables associated with the metabolic syndrome and diabetes i.e. age, BMI, waist circumference, triglycerides, glucose and prevalence of hypertension were higher in the probable HeFH group than in definite HeFH. Subjects with definite HeFH had begun statin therapy 7 years earlier than probable HeFH (TableÂ 1). A total of 103 (5.9%) HeFH were diagnosed of T2DM. The characteristics of subjects with and without T2DM are presented in TableÂ 2. Diabetic patients were older and presented higher BMI, waist circumference, triglycerides, glycosylated hemoglobin, cardiovascular disease and hypertension prevalence than non-diabetics. HDL cholesterol was higher and a positive genetic diagnostic test was more common in non-diabetics than in diabetics. The number of years under statin treatment was higher in diabetics than in non-diabetics (TableÂ 2).   </text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13083</offset><text>-</text></passage><passage><infon key="file">Tab3.xml</infon><infon key="id">Tab3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>13085</offset><text>Prevalence of type 2 diabetes in a reference population and in heterozygous familial hypercholesterolemia patients by sex and age.</text></passage><passage><infon key="file">Tab3.xml</infon><infon key="id">Tab3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th&gt;18â45 years&lt;/th&gt;&lt;th&gt;46â60 years&lt;/th&gt;&lt;th&gt;&amp;gt;60 years&lt;/th&gt;&lt;th&gt;Total&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td colspan=&quot;5&quot;&gt;
&lt;bold&gt;Men&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;General population, N/Total (%)&lt;/td&gt;&lt;td&gt;14/909 (1.54)&lt;/td&gt;&lt;td&gt;69/578 (11.9)&lt;/td&gt;&lt;td&gt;163/687 (23.7)&lt;/td&gt;&lt;td&gt;246/2174 (11.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HeFH, N/Total (%)&lt;/td&gt;&lt;td&gt;2/337 (0.59)&lt;/td&gt;&lt;td&gt;23/338 (6.80)&lt;/td&gt;&lt;td&gt;35/178 (19.7)&lt;/td&gt;&lt;td&gt;60/853 (7.03)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI)&lt;/td&gt;&lt;td&gt;0.382 (0.086â1.688)&lt;/td&gt;&lt;td&gt;0.538 (0.329â0.881)&lt;/td&gt;&lt;td&gt;0.787 (0.523â1.185)&lt;/td&gt;&lt;td&gt;0.593 (0.442â0.796)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;P&lt;/td&gt;&lt;td&gt;0.261&lt;/td&gt;&lt;td&gt;0.012&lt;/td&gt;&lt;td&gt;0.272&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HeFH mutation+, N/Total (%)&lt;/td&gt;&lt;td&gt;2/246 (0.81)&lt;/td&gt;&lt;td&gt;15/188 (7.98)&lt;/td&gt;&lt;td&gt;13/103 (12.6)&lt;/td&gt;&lt;td&gt;30/537 (5.59)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI)&lt;/td&gt;&lt;td&gt;0.524 (0.118â2.231)&lt;/td&gt;&lt;td&gt;0.639 (0.356â1.147)&lt;/td&gt;&lt;td&gt;0.478 (0.263â0.870)&lt;/td&gt;&lt;td&gt;0.470 (0.319â0.694)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;P&lt;/td&gt;&lt;td&gt;0.545&lt;/td&gt;&lt;td&gt;0.141&lt;/td&gt;&lt;td&gt;0.010&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;5&quot;&gt;
&lt;bold&gt;Women&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;General population, N/Total (%)&lt;/td&gt;&lt;td&gt;9/1222 (0.74)&lt;/td&gt;&lt;td&gt;54/818 (6.60)&lt;/td&gt;&lt;td&gt;170/858 (19.8)&lt;/td&gt;&lt;td&gt;233/2898 (8.04)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HeFH, N /Total (%)&lt;/td&gt;&lt;td&gt;2/277 (0.72)&lt;/td&gt;&lt;td&gt;18/318 (5.66)&lt;/td&gt;&lt;td&gt;23/285 (8.07)&lt;/td&gt;&lt;td&gt;43/880 (4.89)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI)&lt;/td&gt;&lt;td&gt;0.980 (0.211â4.562)&lt;/td&gt;&lt;td&gt;0.849 (0.489â1.471)&lt;/td&gt;&lt;td&gt;0.355 (0.225â0.562)&lt;/td&gt;&lt;td&gt;0.588 (0.421â0.821)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;P&lt;/td&gt;&lt;td&gt;0.979&lt;/td&gt;&lt;td&gt;0.684&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;td&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HeFH mutation+, N/Total (%)&lt;/td&gt;&lt;td&gt;2/221 (0.90)&lt;/td&gt;&lt;td&gt;6/185 (3.24)&lt;/td&gt;&lt;td&gt;10/157 (6.37)&lt;/td&gt;&lt;td&gt;18/563 (3.20)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI)&lt;/td&gt;&lt;td&gt;1.455 (0.359â5.093)&lt;/td&gt;&lt;td&gt;0.508 (0.222â1.164)&lt;/td&gt;&lt;td&gt;0.287 (0.150â0.549)&lt;/td&gt;&lt;td&gt;0.387 (0.239â0.627)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;P&lt;/td&gt;&lt;td&gt;0.597&lt;/td&gt;&lt;td&gt;0.087&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;5&quot;&gt;
&lt;bold&gt;All&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;General population, N/Total (%)&lt;/td&gt;&lt;td&gt;23/2131 (1.08)&lt;/td&gt;&lt;td&gt;123/1396 (8.81)&lt;/td&gt;&lt;td&gt;333/1545 (21.6)&lt;/td&gt;&lt;td&gt;479/5072 (9.44)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HeFH, N /Total (%)&lt;/td&gt;&lt;td&gt;4/614 (0.65)&lt;/td&gt;&lt;td&gt;41/656 (6.25)&lt;/td&gt;&lt;td&gt;58/463 (12.5)&lt;/td&gt;&lt;td&gt;103/1733 (5.94)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI)&lt;/td&gt;&lt;td&gt;0.601 (0.207â1.744)&lt;/td&gt;&lt;td&gt;0.689 (0.478â0.995)&lt;/td&gt;&lt;td&gt;0.521 (0.386â0.704)&lt;/td&gt;&lt;td&gt;0.606 (0.486â0.755)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;P&lt;/td&gt;&lt;td&gt;0.343&lt;/td&gt;&lt;td&gt;0.046&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HeFH mutation+, N/Total (%)&lt;/td&gt;&lt;td&gt;4/467 (0.86)&lt;/td&gt;&lt;td&gt;21/373 (5.63)&lt;/td&gt;&lt;td&gt;23/260 (8.85)&lt;/td&gt;&lt;td&gt;48/1100 (4.36)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI)&lt;/td&gt;&lt;td&gt;0.791 (0.273â2.300)&lt;/td&gt;&lt;td&gt;0.617 (0.383â0.995)&lt;/td&gt;&lt;td&gt;0.353 (0.226â0.551)&lt;/td&gt;&lt;td&gt;0.438 (0.323â0.593)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;P&lt;/td&gt;&lt;td&gt;0.667&lt;/td&gt;&lt;td&gt;0.046&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13216</offset><text>	18â45 years	46â60 years	&gt;60 years	Total	 	Men	 	General population, N/Total (%)	14/909 (1.54)	69/578 (11.9)	163/687 (23.7)	246/2174 (11.3)	 	HeFH, N/Total (%)	2/337 (0.59)	23/338 (6.80)	35/178 (19.7)	60/853 (7.03)	 	Odds ratio (95% CI)	0.382 (0.086â1.688)	0.538 (0.329â0.881)	0.787 (0.523â1.185)	0.593 (0.442â0.796)	 	P	0.261	0.012	0.272	&lt;0.001	 	HeFH mutation+, N/Total (%)	2/246 (0.81)	15/188 (7.98)	13/103 (12.6)	30/537 (5.59)	 	Odds ratio (95% CI)	0.524 (0.118â2.231)	0.639 (0.356â1.147)	0.478 (0.263â0.870)	0.470 (0.319â0.694)	 	P	0.545	0.141	0.010	&lt;0.001	 	Women	 	General population, N/Total (%)	9/1222 (0.74)	54/818 (6.60)	170/858 (19.8)	233/2898 (8.04)	 	HeFH, N /Total (%)	2/277 (0.72)	18/318 (5.66)	23/285 (8.07)	43/880 (4.89)	 	Odds ratio (95% CI)	0.980 (0.211â4.562)	0.849 (0.489â1.471)	0.355 (0.225â0.562)	0.588 (0.421â0.821)	 	P	0.979	0.684	&lt;0.001	0.002	 	HeFH mutation+, N/Total (%)	2/221 (0.90)	6/185 (3.24)	10/157 (6.37)	18/563 (3.20)	 	Odds ratio (95% CI)	1.455 (0.359â5.093)	0.508 (0.222â1.164)	0.287 (0.150â0.549)	0.387 (0.239â0.627)	 	P	0.597	0.087	&lt;0.001	&lt;0.001	 	All	 	General population, N/Total (%)	23/2131 (1.08)	123/1396 (8.81)	333/1545 (21.6)	479/5072 (9.44)	 	HeFH, N /Total (%)	4/614 (0.65)	41/656 (6.25)	58/463 (12.5)	103/1733 (5.94)	 	Odds ratio (95% CI)	0.601 (0.207â1.744)	0.689 (0.478â0.995)	0.521 (0.386â0.704)	0.606 (0.486â0.755)	 	P	0.343	0.046	&lt;0.001	&lt;0.001	 	HeFH mutation+, N/Total (%)	4/467 (0.86)	21/373 (5.63)	23/260 (8.85)	48/1100 (4.36)	 	Odds ratio (95% CI)	0.791 (0.273â2.300)	0.617 (0.383â0.995)	0.353 (0.226â0.551)	0.438 (0.323â0.593)	 	P	0.667	0.046	&lt;0.001	&lt;0.001	 	</text></passage><passage><infon key="file">41598_2017_6101_Fig2_HTML.jpg</infon><infon key="id">Fig2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>14888</offset><text>Prevalence of type 2 diabetes mellitus in heterozygous familial hypercholesterolemic patients according to LDL-cholesterol concentrations.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15027</offset><text>The overall and divided-byage group gender and genetic diagnosis prevalence of T2DM in HeFH with the odds ratios (OR) compared with the prevalence of the age- and gender-adjusted Spanish population are shown in TableÂ 3. T2DM was more common in males than in females and increased with age in HeFH and in the general population. However, T2DM was significantly less frequent among HeFH, 5.94% versus 9.44% in the general population (OR: 0.606, 95% CI 486â0.755, pâ&lt;â0.001). This difference was also present when only HeFH with a positive genetic diagnosis (OR: 0.438, 95% CI 0.323â0.593, pâ&lt;â0.001) were considered.T2DM protection in HeFH was similar in all age groups and in both genders, but reached statistical significance only in older groups, owing to the low T2DM prevalence in subjects under 46 years of age (TableÂ 3). Subjects with a functional mutation in candidate genes were older, had higher BMI, waist circumference, triglyceride and glucose concentrations, and a higher prevalence of hypertension and T2DM than HeFH without mutations (Supplementary Table). On the other hand, no differences were observed in the prevalence of T2DM when patients were separated into different subgroups according to LDL-cholesterol concentrations (Fig.Â 2).  </text></passage><passage><infon key="file">Tab4.xml</infon><infon key="id">Tab4</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>16297</offset><text>Factors associated with the presence of type 2 diabetes mellitus in clinically-defined heterozygous familial hypercholesterolemia patients (â¥6 DLCN points).</text></passage><passage><infon key="file">Tab4.xml</infon><infon key="id">Tab4</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th&gt;Standard coeff. (Î²)&lt;/th&gt;&lt;th&gt;Exp (B)&lt;/th&gt;&lt;th&gt;95% CI&lt;/th&gt;&lt;th&gt;
&lt;italic&gt;P&lt;/italic&gt;
&lt;/th&gt;&lt;th&gt;R&lt;sup&gt;2&lt;/sup&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Sex, male&lt;/td&gt;&lt;td&gt;0.649&lt;/td&gt;&lt;td&gt;1.913&lt;/td&gt;&lt;td&gt;1.204â3.040&lt;/td&gt;&lt;td&gt;0.006&lt;/td&gt;&lt;td rowspan=&quot;6&quot;&gt;0.261&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Age, years&lt;/td&gt;&lt;td&gt;0.050&lt;/td&gt;&lt;td&gt;1.052&lt;/td&gt;&lt;td&gt;1.030â1.074&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;BMI, kg/m&lt;sup&gt;2&lt;/sup&gt;
&lt;/td&gt;&lt;td&gt;0.021&lt;/td&gt;&lt;td&gt;1.021&lt;/td&gt;&lt;td&gt;1.007â1.035&lt;/td&gt;&lt;td&gt;0.004&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hypertension, yes&lt;/td&gt;&lt;td&gt;1.522&lt;/td&gt;&lt;td&gt;4.582&lt;/td&gt;&lt;td&gt;2.834â7.407&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Triglycerides, mg/dL&lt;/td&gt;&lt;td&gt;0.002&lt;/td&gt;&lt;td&gt;1.002&lt;/td&gt;&lt;td&gt;1.001â1.003&lt;/td&gt;&lt;td&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Statin therapy, years&lt;/td&gt;&lt;td&gt;0.031&lt;/td&gt;&lt;td&gt;1.031&lt;/td&gt;&lt;td&gt;1.003â1.060&lt;/td&gt;&lt;td&gt;0.03&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>16456</offset><text>	Standard coeff. (Î²)	Exp (B)	95% CI	P	R2	 	Sex, male	0.649	1.913	1.204â3.040	0.006	0.261	 	Age, years	0.050	1.052	1.030â1.074	&lt;0.001	 	BMI, kg/m2	0.021	1.021	1.007â1.035	0.004	 	Hypertension, yes	1.522	4.582	2.834â7.407	&lt;0.001	 	Triglycerides, mg/dL	0.002	1.002	1.001â1.003	0.001	 	Statin therapy, years	0.031	1.031	1.003â1.060	0.03	 	</text></passage><passage><infon key="file">Tab4.xml</infon><infon key="id">Tab4</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>16805</offset><text>DLCN denotes Dutch Lipid Clinic Network; BMI, body mass index.</text></passage><passage><infon key="file">Tab4.xml</infon><infon key="id">Tab4</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>16868</offset><text>Independent variables included in the model: sex, age, BMI, smoking status, hypertension, tendon xanthomas, baseline LDL and HDL cholesterol and triglyceride concentrations, genetic diagnosis and statin therapy duration.</text></passage><passage><infon key="file">Tab5.xml</infon><infon key="id">Tab5</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>17089</offset><text>Factors associated with the presence of type 2 diabetes mellitus in genetically-defined heterozygous familial hypercholesterolemia patients (with a pathogenic mutation in LDLR, APOB or PCSK9 genes).</text></passage><passage><infon key="file">Tab5.xml</infon><infon key="id">Tab5</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th&gt;Standard coeff. (Î²)&lt;/th&gt;&lt;th&gt;Exp (B)&lt;/th&gt;&lt;th&gt;95% CI&lt;/th&gt;&lt;th&gt;
&lt;italic&gt;p&lt;/italic&gt;
&lt;/th&gt;&lt;th&gt;R&lt;sup&gt;2&lt;/sup&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Sex, male&lt;/td&gt;&lt;td&gt;0.713&lt;/td&gt;&lt;td&gt;2.041&lt;/td&gt;&lt;td&gt;1.081â3.853&lt;/td&gt;&lt;td&gt;0.028&lt;/td&gt;&lt;td rowspan=&quot;4&quot;&gt;0.195&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;BMI, kg/m&lt;sup&gt;2&lt;/sup&gt;
&lt;/td&gt;&lt;td&gt;0.018&lt;/td&gt;&lt;td&gt;1.018&lt;/td&gt;&lt;td&gt;1.003â1.034&lt;/td&gt;&lt;td&gt;0.022&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hypertension, yes&lt;/td&gt;&lt;td&gt;2.072&lt;/td&gt;&lt;td&gt;7.942&lt;/td&gt;&lt;td&gt;4.249â14.845&lt;/td&gt;&lt;td&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Statin therapy, years&lt;/td&gt;&lt;td&gt;0.044&lt;/td&gt;&lt;td&gt;1.045&lt;/td&gt;&lt;td&gt;1.002â1.090&lt;/td&gt;&lt;td&gt;0.040&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>17288</offset><text>	Standard coeff. (Î²)	Exp (B)	95% CI	p	R2	 	Sex, male	0.713	2.041	1.081â3.853	0.028	0.195	 	BMI, kg/m2	0.018	1.018	1.003â1.034	0.022	 	Hypertension, yes	2.072	7.942	4.249â14.845	&lt;0.001	 	Statin therapy, years	0.044	1.045	1.002â1.090	0.040	 	</text></passage><passage><infon key="file">Tab5.xml</infon><infon key="id">Tab5</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>17538</offset><text>BMI denotes body mass index.</text></passage><passage><infon key="file">Tab5.xml</infon><infon key="id">Tab5</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>17567</offset><text>Independent variables included in the model: sex, age, BMI, smoking status, hypertension, tendon xanthomas, baseline LDL and HDL cholesterol and triglyceride concentrations, genetic diagnosis and statin therapy duration.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17788</offset><text>Risk factors for HeFH patients developing T2DM are presented in TableÂ 4 for the whole HeFH group and in TableÂ 5 for patients with a positive genetic diagnosis. Male sex, BMI, hypertension and years on statin therapy were independently associated with the presence of T2DM in both groups. These risk factors could account for up to 26% of the variability in presenting T2DM (TableÂ 4). Other factors such as age, BMI, smoking status, xanthomas, baseline LDL, HDL cholesterol and triglyceride concentrations did not reach statistical significance.  </text></passage><passage><infon key="file">Tab6.xml</infon><infon key="id">Tab6</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>18338</offset><text>Effect of phenotype severity in heterozygous familial hypercholesterolemia on type 2 diabetes prevalence.</text></passage><passage><infon key="file">Tab6.xml</infon><infon key="id">Tab6</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Comparison&lt;/th&gt;&lt;th&gt;All&lt;/th&gt;&lt;th&gt;HeFH with LDL &amp;lt;250âmg/dL&lt;/th&gt;&lt;th&gt;HeFH with LDL â¥250âmg/dL&lt;/th&gt;&lt;th&gt;HeFH with &amp;gt;8 points&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI) Unadjusted&lt;/td&gt;&lt;td&gt;0.821 (0.429â1.572)&lt;/td&gt;&lt;td&gt;0.736 (0.287â1.887)&lt;/td&gt;&lt;td&gt;2.384 (0.557â10.207)&lt;/td&gt;&lt;td&gt;0.707 (0.294â1.696)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI) Adjusted&lt;sup&gt;*&lt;/sup&gt;
&lt;/td&gt;&lt;td&gt;0.954 (0.488â1.866)&lt;/td&gt;&lt;td&gt;1.386 (0.498â3.852)&lt;/td&gt;&lt;td&gt;2.395 (0.549â10.444)&lt;/td&gt;&lt;td&gt;0.747 (0.303â1.839)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI) Adjusted&lt;sup&gt;â &lt;/sup&gt;
&lt;/td&gt;&lt;td&gt;0.936 (0.478â1.835)&lt;/td&gt;&lt;td&gt;1.388 (0.496â3.887)&lt;/td&gt;&lt;td&gt;2.806 (0.631â12.478)&lt;/td&gt;&lt;td&gt;0.735 (0.298â1.813)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Odds ratio (95% CI) Adjusted&lt;sup&gt;â¡&lt;/sup&gt;
&lt;/td&gt;&lt;td&gt;1.072 (0.533â2.155)&lt;/td&gt;&lt;td&gt;1.474 (0.512â4.243)&lt;/td&gt;&lt;td&gt;3.056 (0.670â13.930)&lt;/td&gt;&lt;td&gt;0.877 (0.341â2.250)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>18444</offset><text>Comparison	All	HeFH with LDL &lt;250âmg/dL	HeFH with LDL â¥250âmg/dL	HeFH with &gt;8 points	 	Odds ratio (95% CI) Unadjusted	0.821 (0.429â1.572)	0.736 (0.287â1.887)	2.384 (0.557â10.207)	0.707 (0.294â1.696)	 	Odds ratio (95% CI) Adjusted*	0.954 (0.488â1.866)	1.386 (0.498â3.852)	2.395 (0.549â10.444)	0.747 (0.303â1.839)	 	Odds ratio (95% CI) Adjustedâ 	0.936 (0.478â1.835)	1.388 (0.496â3.887)	2.806 (0.631â12.478)	0.735 (0.298â1.813)	 	Odds ratio (95% CI) Adjustedâ¡	1.072 (0.533â2.155)	1.474 (0.512â4.243)	3.056 (0.670â13.930)	0.877 (0.341â2.250)	 	</text></passage><passage><infon key="file">Tab6.xml</infon><infon key="id">Tab6</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>19027</offset><text>
*Adjusted for age, sex and years of statin use.</text></passage><passage><infon key="file">Tab6.xml</infon><infon key="id">Tab6</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>19076</offset><text>
â Adjusted for age, sex, years of statin use and body mass index.</text></passage><passage><infon key="file">Tab6.xml</infon><infon key="id">Tab6</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>19144</offset><text>
â¡Adjusted for age, sex, years of statin use, body mass index, triglycerides, and hypertension.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19242</offset><text>Finally, different regression models were applied to identify the association of a pathogenic mutation in LDLR, APOB or PCSK9 in the presence of T2DM. None of the models with different adjustments showed any significant association of a positive genetic diagnosis with T2DM (TableÂ 6). </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>19529</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19540</offset><text>The prevalence of T2DM in HeFH patients in the present study was 5.9%, lower than the known 9.4% prevalence in the age and sex-adjusted Spanish population. In a Dutch cohort, the prevalence of T2DM in HeFH patients was 1.75% compared to 2.93% in unaffected relatives. This may be partially explained by younger age in the Dutch HeFH cohort, more than one decade, compared to our population and the different criteria used in the diagnosis of T2DM between studies, only auto-reported in the Dutch cohort. Nevertheless, our study confirms the Dutch results in a completely different population, showing that HeFH subjects present an approximately 50% lower T2DM risk than the general population. This T2DM protection has been questioned in favor of a role for cellular cholesterol metabolism in the pathogenesis of type 2 diabetes.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20370</offset><text>Besides this confirmatory information, several important conclusions can be drawn from our study. First, the LDL cholesterol concentration before the start of lipid-lowering treatment did not play a major role in T2DM protection in HeFH in our study. The lower risk of T2DM appeared in a large LDL cholesterol range, and the LDL cholesterol concentration did not significantly affect T2DM risk. Although there is in-vivo and ex-vivo evidence showing that LDL concentration modulates insulin secretion and pancreatic Î²-cell survival, large prospective studies showed no significant effect of LDL cholesterol on T2DM risk, in contrast to the association with high triglycerides or low HDL cholesterol that has been repeatedly demonstrated. In human Î² cell islets, LDL overload lowered insulin secretion and diet-induced hypercholesterolemia also reduced insulin secretion in mice; however, this diabetogenic effect of hypercholesterolemic diets has also been associated with saturated fatty acid accumulation rather than with cholesterol. Second, in the present study, no differences were observed in T2DM prevalence according to the presence or absence of causative gene mutations responsible for HeFH. Our study is the first to include clinically-diagnosed patients and analyzed T2DM prevalence according to LDLR, APOB or PCSK9 mutations. Besseling et al. included HeFH only with a confirmed pathogenic mutation, and found a dose-dependent association in HeFH subjects with LDLR negative mutations who had a lower T2DM prevalence than HeFH carriers of defective LDLR or APOB mutations, suggesting that the severity of the genetic defect plays a role in T2DM protection. The implication of the LDL receptor in glucose homeostasis is controversial, since the deleterious effect of cholesterol overload on insulin secretion by pancreatic Î² cells was similar in LDLR-/- knockout or wild-type mice, and oxidized LDL, which does not use the LDL receptor, was found to be a major contributor to Î² cell dysfunction. Furthermore, some FH-causing mutations seem to be associated with a higher T2DM risk. In our study, the presence of any LDLR/APOB/PCSK9 mutation was less common in HeFH with than without T2DM; however, these differences disappeared after adjustment for confounders unrelated to LDL receptor function.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>22691</offset><text>Third, the factors associated with the presence of T2DM in HeFH are the same as those present in the general population, including statin use. The cluster of abnormalities closely associated with insulin resistance: high blood pressure, high triglycerides, low HDL cholesterol, increased BMI and older age, are also strongly related to the presence of T2DM in HeFH, as previously described. In this observational, cross-sectional study, we could not calculate whether the impact of T2DM risk factors is different in HeFH than in non-FH; however, we did have a close approximation for statin use as this information was available. Statin use preceded the diagnosis of T2DM in most cases and the risk associated with statin use was identical to that observed in statin trials after adjustment for insulin-resistance markers.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23514</offset><text>Thus, if LDL cholesterol or LDL receptor function itself are not responsible for the T2DM protection in HeFH, which mechanisms are involved? Potential explanations have been previously put forward: the observational cross-sectional design without power to establish causality; the possibility of unexplored potential confounders; a healthier lifestyle after receiving the diagnosis of HeFH; or a shorter life-expectancy in patients with HeFH and T2DM could be responsible for this observation. The HDL particle is also an unexplored potential protective factor of T2DM in HeFH. In HeFH, HDL cholesterol is usually within normal range and, in contrast with other dyslipidemias, HDL particle size and number are in antiatherogenic range. Indeed, the Dutch HeFH patients were leaner, smoked less and had lower triglycerides than their unaffected relatives without a clear explanation, except for a healthier lifestyle associated with the diagnosis. In our cohort of HeFH patients, the prevalence of hypertension, overweight, obesity and tobacco use was much lower than that observed in the Spanish general population. Altogether, these data suggest that environmental factors could be involved in this T2DM protection in these patients cared for in highly specialized lipid units. Actually, the reduction in BMI compared with the reference population could explain one third of the lower risk of T2DM. A large case-control study is underway to try to answer these questions.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24986</offset><text>Our study has some limitations. In this respect, the number of HeFH with T2DM was relatively low, but the concurrence with previous data supports the T2DM protection. Our study was cross-sectional, and results other than prevalence should thus be taken with caution. The sample was composed of middle-aged men and women from a Mediterranean country, with traditionally lower coronary heart disease rates than other populations, albeit with a high prevalence of T2DM. Furthermore, patients included in the Spanish Dyslipidemia Registry are treated with a standardized protocol promoting the use of high-intensity lipid-lowering treatment in highly specialized Lipid Clinics; thus, the results cannot be easily extrapolated to other clinical settings. Finally, the observed prevalence of T2DM in HeFH could be underestimated since patients with HeFH are at increased risk for cardiovascular disease and some will have died before their inclusion in the Dyslipidemia Spanish registry. If HeFH was associated with T2DM, the possibility of early death from cardiovascular causes was even higher. On the other hand, T2DM prevalence increases with age and HeFH patients who died prematurely might have been less likely to develop T2DM; thus, an overestimation of T2DM in our cohort is also possible. In any event, the mean age of HeFH patients was around 55 years, and the prevalence of T2DM increased with age in both HeFH patients and in the general population.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>26443</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>26455</offset><text>In summary, the absolute prevalence of T2DM in patients with HeFH was 40% lower than that observed in the general population matched for age and sex. Risk factors independently associated with the presence of T2DM in subjects with HeFH were age, male sex, BMI, baseline triglycerides, hypertension and years of statin treatment. LDL cholesterol concentrations and the presence of mutations in FH-causing genes were not associated with the presence of T2DM in HeFH subjects.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>26929</offset><text>Electronic supplementary material</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>26963</offset><text>Electronic supplementary material</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>26997</offset><text> Supplementary information accompanies this paper at doi:10.1038/s41598-017-06101-6 </text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27082</offset><text> Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title</infon><offset>27220</offset><text>Author Contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27241</offset><text>E.C.: acquisition, analysis, and interpretation of data for the work; drafting the work; S.P.-C.: acquisition and statistical analysis of data. V.M.-B.: analysis and interpretation of data for the work. N.P.: interpretation of data for the work, revising it critically. R.S.: acquisition and statistical analysis of data. E.R.: interpretation of data for the work, revising it critically. J.F.A.: interpretation of data for the work, revising it critically. J.P.: data acquisition. F.A.: data acquisition. C.L.: data acquisition. F.C.: conception and design of the work; analysis and interpretation of data for the work. J.P.-B.: conception and design of the work; analysis and interpretation of data for the work; drafting the work. All authors have read and approved the final manuscript.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>28032</offset><text>Competing Interests</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>28052</offset><text>The authors declare that they have no competing interests.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>28111</offset><text>References</text></passage><passage><infon key="fpage">962</infon><infon key="lpage">971</infon><infon key="name_0">surname:Hovingh;given-names:GK</infon><infon key="name_1">surname:Davidson;given-names:MH</infon><infon key="name_2">surname:Kastelein;given-names:JJ</infon><infon key="name_3">surname:OâConnor;given-names:AM</infon><infon key="pub-id_doi">10.1093/eurheartj/eht015</infon><infon key="pub-id_pmid">23416791</infon><infon key="section_type">REF</infon><infon key="source">Eur. Heart. J.</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2013</infon><offset>28122</offset><text>Diagnosis and treatment of familial hypercholesterolaemia</text></passage><passage><infon key="fpage">2113</infon><infon key="lpage">2121</infon><infon key="name_0">surname:Cenarro;given-names:A</infon><infon key="pub-id_doi">10.1210/jc.2015-3874</infon><infon key="pub-id_pmid">27014949</infon><infon key="section_type">REF</infon><infon key="source">J. Clin. Endocrinol. Metab.</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">2016</infon><offset>28180</offset><text>The p.Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes</text></passage><passage><infon key="fpage">366</infon><infon key="lpage">373</infon><infon key="name_0">surname:Vohl;given-names:MC</infon><infon key="pub-id_doi">10.1046/j.1365-2362.1997.1250669.x</infon><infon key="pub-id_pmid">9179542</infon><infon key="section_type">REF</infon><infon key="source">Eur. J. Clin. Invest.</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">1997</infon><offset>28326</offset><text>Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia</text></passage><passage><infon key="fpage">1029</infon><infon key="lpage">1036</infon><infon key="name_0">surname:Besseling;given-names:J</infon><infon key="name_1">surname:Kastelein;given-names:JJ</infon><infon key="name_2">surname:Defesche;given-names:JC</infon><infon key="name_3">surname:Hutten;given-names:BA</infon><infon key="name_4">surname:Hovingh;given-names:GK</infon><infon key="pub-id_doi">10.1001/jama.2015.1206</infon><infon key="pub-id_pmid">25756439</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">313</infon><infon key="year">2015</infon><offset>28512</offset><text>Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus</text></passage><passage><infon key="fpage">1016</infon><infon key="lpage">1017</infon><infon key="name_0">surname:Preiss;given-names:D</infon><infon key="name_1">surname:Sattar;given-names:N</infon><infon key="pub-id_doi">10.1001/jama.2015.1275</infon><infon key="pub-id_pmid">25756436</infon><infon key="section_type">REF</infon><infon key="source">JAMA.</infon><infon key="type">ref</infon><infon key="volume">313</infon><infon key="year">2015</infon><offset>28605</offset><text>Does the LDL receptor play a role in the risk of developing type 2 diabetes?</text></passage><passage><infon key="fpage">735</infon><infon key="lpage">742</infon><infon key="name_0">surname:Sattar;given-names:N</infon><infon key="pub-id_doi">10.1016/S0140-6736(09)61965-6</infon><infon key="pub-id_pmid">20167359</infon><infon key="section_type">REF</infon><infon key="source">Lancet.</infon><infon key="type">ref</infon><infon key="volume">375</infon><infon key="year">2010</infon><offset>28682</offset><text>Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials</text></passage><passage><infon key="fpage">2556</infon><infon key="lpage">2564</infon><infon key="name_0">surname:Preiss;given-names:D</infon><infon key="pub-id_doi">10.1001/jama.2011.860</infon><infon key="pub-id_pmid">21693744</infon><infon key="section_type">REF</infon><infon key="source">JAMA.</infon><infon key="type">ref</infon><infon key="volume">305</infon><infon key="year">2011</infon><offset>28779</offset><text>Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis</text></passage><passage><infon key="fpage">471</infon><infon key="lpage">475</infon><infon key="name_0">surname:Katsiki;given-names:N</infon><infon key="name_1">surname:Rizzo;given-names:M</infon><infon key="name_2">surname:Mikhailidis;given-names:DP</infon><infon key="name_3">surname:Mantzoros;given-names:CS</infon><infon key="pub-id_doi">10.1016/j.metabol.2014.11.001</infon><infon key="pub-id_pmid">25484289</infon><infon key="section_type">REF</infon><infon key="source">Metabolism.</infon><infon key="type">ref</infon><infon key="volume">64</infon><infon key="year">2015</infon><offset>28885</offset><text>New-onset diabetes and statins: throw the bath water out, but, please, keep the baby!</text></passage><passage><infon key="fpage">20</infon><infon key="name_0">surname:Miller;given-names:PE</infon><infon key="name_1">surname:Martin;given-names:SS</infon><infon key="pub-id_doi">10.1007/s11883-016-0578-1</infon><infon key="pub-id_pmid">26973129</infon><infon key="section_type">REF</infon><infon key="source">Curr. Atheroscler. Rep.</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2016</infon><offset>28971</offset><text>Approach to statin use in 2016: an update</text></passage><passage><infon key="fpage">3478</infon><infon key="lpage">3490</infon><infon key="name_0">surname:Nordestgaard;given-names:BG</infon><infon key="pub-id_doi">10.1093/eurheartj/eht273</infon><infon key="pub-id_pmid">23956253</infon><infon key="section_type">REF</infon><infon key="source">Eur. Heart. J.</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2013</infon><offset>29013</offset><text>European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society</text></passage><passage><infon key="fpage">88</infon><infon key="lpage">93</infon><infon key="name_0">surname:Soriguer;given-names:F</infon><infon key="pub-id_doi">10.1007/s00125-011-2336-9</infon><infon key="pub-id_pmid">21987347</infon><infon key="section_type">REF</infon><infon key="source">Diabetologia.</infon><infon key="type">ref</infon><infon key="volume">55</infon><infon key="year">2012</infon><offset>29275</offset><text>Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study</text></passage><passage><infon key="fpage">362</infon><infon key="lpage">372</infon><infon key="name_0">surname:Stef;given-names:MA</infon><infon key="pub-id_doi">10.1016/j.jmoldx.2013.01.005</infon><infon key="pub-id_pmid">23537714</infon><infon key="section_type">REF</infon><infon key="source">J. Mol. Diagn.</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2013</infon><offset>29369</offset><text>A DNA microarray for the detection of point mutations and copy number variation causing familial hypercholesterolemia in Europe</text></passage><passage><infon key="fpage">317</infon><infon key="lpage">324</infon><infon key="name_0">surname:Paul;given-names:R</infon><infon key="name_1">surname:Choudhury;given-names:A</infon><infon key="name_2">surname:Choudhury;given-names:S</infon><infon key="name_3">surname:Mazumder;given-names:MK</infon><infon key="name_4">surname:Borah;given-names:A</infon><infon key="pub-id_doi">10.1097/MPA.0000000000000486</infon><infon key="pub-id_pmid">26692438</infon><infon key="section_type">REF</infon><infon key="source">Pancreas.</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">2016</infon><offset>29497</offset><text>Cholesterol in pancreatic Î²-cell death and dysfunction: underlying mechanisms and pathological implications</text></passage><passage><infon key="fpage">3101</infon><infon key="lpage">3108</infon><infon key="name_0">surname:von Eckardstein;given-names:A</infon><infon key="name_1">surname:Schulte;given-names:H</infon><infon key="name_2">surname:Assmann;given-names:G</infon><infon key="pub-id_doi">10.1210/jcem.85.9.6773</infon><infon key="pub-id_pmid">10999793</infon><infon key="section_type">REF</infon><infon key="source">J. Clin. Endocrinol. Metab.</infon><infon key="type">ref</infon><infon key="volume">85</infon><infon key="year">2000</infon><offset>29608</offset><text>Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular MÃ¼nster</text></passage><passage><infon key="fpage">1418</infon><infon key="lpage">1429</infon><infon key="name_0">surname:Imamura;given-names:F</infon><infon key="pub-id_doi">10.1093/aje/kws440</infon><infon key="pub-id_pmid">23707958</infon><infon key="section_type">REF</infon><infon key="source">Am. J. Epidemiol.</infon><infon key="type">ref</infon><infon key="volume">177</infon><infon key="year">2013</infon><offset>29833</offset><text>Risk factors for type 2 diabetes mellitus preceded by Î²-cell dysfunction, insulin resistance, or both in older adults: the Cardiovascular Health Study</text></passage><passage><infon key="fpage">4521</infon><infon key="lpage">4530</infon><infon key="name_0">surname:Rutti;given-names:S</infon><infon key="pub-id_doi">10.1210/en.2009-0252</infon><infon key="pub-id_pmid">19628574</infon><infon key="section_type">REF</infon><infon key="source">Endocrinology.</infon><infon key="type">ref</infon><infon key="volume">150</infon><infon key="year">2009</infon><offset>29987</offset><text>Low and high density lipoproteins modulate function, apoptosis and proliferation of primary human and murine pancreatic beta cells</text></passage><passage><infon key="fpage">1110</infon><infon key="lpage">1119</infon><infon key="name_0">surname:Kruit;given-names:JK</infon><infon key="pub-id_doi">10.1007/s00125-010-1691-2</infon><infon key="pub-id_pmid">20229095</infon><infon key="section_type">REF</infon><infon key="source">Diabetologia.</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">2010</infon><offset>30118</offset><text>Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice</text></passage><passage><infon key="fpage">26569</infon><infon key="lpage">26582</infon><infon key="name_0">surname:Boslem;given-names:E</infon><infon key="pub-id_doi">10.1074/jbc.M113.489310</infon><infon key="pub-id_pmid">23897822</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">288</infon><infon key="year">2013</infon><offset>30301</offset><text>Alteration of endoplasmic reticulum lipid rafts contributes to lipotoxicity in pancreatic Î²-cells</text></passage><passage><infon key="fpage">183</infon><infon key="lpage">190</infon><infon key="name_0">surname:Bonfleur;given-names:ML</infon><infon key="pub-id_doi">10.1016/j.bbalip.2009.10.012</infon><infon key="pub-id_pmid">19913637</infon><infon key="section_type">REF</infon><infon key="source">Biochim. Biophys. Acta</infon><infon key="type">ref</infon><infon key="volume">1801</infon><infon key="year">2010</infon><offset>30402</offset><text>Primary hypercholesterolaemia impairs glucose homeostasis and insulin secretion in low-density lipoprotein receptor knockout mice independently of high-fat diet and obesity</text></passage><passage><infon key="fpage">1304</infon><infon key="lpage">1314</infon><infon key="name_0">surname:Abderrahmani;given-names:A</infon><infon key="pub-id_doi">10.1007/s00125-007-0642-z</infon><infon key="pub-id_pmid">17437081</infon><infon key="section_type">REF</infon><infon key="source">Diabetologia.</infon><infon key="type">ref</infon><infon key="volume">50</infon><infon key="year">2007</infon><offset>30575</offset><text>Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells</text></passage><passage><infon key="fpage">786</infon><infon key="lpage">793</infon><infon key="name_0">surname:Saavedra;given-names:YG</infon><infon key="name_1">surname:Dufour;given-names:R</infon><infon key="name_2">surname:Baass;given-names:A</infon><infon key="pub-id_doi">10.1016/j.jacl.2015.08.005</infon><infon key="pub-id_pmid">26687699</infon><infon key="section_type">REF</infon><infon key="source">J. Clin. Lipidol.</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2015</infon><offset>30739</offset><text>Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk</text></passage><passage><infon key="fpage">421</infon><infon key="lpage">422</infon><infon key="name_0">surname:Reaven;given-names:GM</infon><infon key="pub-id_doi">10.1111/joim.12537</infon><infon key="pub-id_pmid">27452159</infon><infon key="section_type">REF</infon><infon key="source">J. Intern. Med.</infon><infon key="type">ref</infon><infon key="volume">280</infon><infon key="year">2016</infon><offset>30829</offset><text>Statins, familial hypercholesterolemia and type 2 diabetes</text></passage><passage><infon key="fpage">79</infon><infon key="lpage">84</infon><infon key="name_0">surname:Fuentes;given-names:F</infon><infon key="pub-id_doi">10.1016/j.ijcard.2015.07.107</infon><infon key="pub-id_pmid">26296047</infon><infon key="section_type">REF</infon><infon key="source">Int. J. Cardiol.</infon><infon key="type">ref</infon><infon key="volume">201</infon><infon key="year">2015</infon><offset>30888</offset><text>SAFEHEART Investigators. Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study</text></passage><passage><infon key="fpage">565</infon><infon key="lpage">571</infon><infon key="name_0">surname:Ridker;given-names:PM</infon><infon key="name_1">surname:Pradhan;given-names:A</infon><infon key="name_2">surname:MacFadyen;given-names:JG</infon><infon key="name_3">surname:Libby;given-names:P</infon><infon key="name_4">surname:Glynn;given-names:RJ</infon><infon key="pub-id_doi">10.1016/S0140-6736(12)61190-8</infon><infon key="pub-id_pmid">22883507</infon><infon key="section_type">REF</infon><infon key="source">Lancet.</infon><infon key="type">ref</infon><infon key="volume">380</infon><infon key="year">2012</infon><offset>31030</offset><text>Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial</text></passage><passage><infon key="fpage">26</infon><infon key="lpage">32</infon><infon key="name_0">surname:von Eckardstein;given-names:A</infon><infon key="name_1">surname:Sibler;given-names:RA</infon><infon key="pub-id_doi">10.1097/MOL.0b013e3283412279</infon><infon key="pub-id_pmid">21102330</infon><infon key="section_type">REF</infon><infon key="source">Curr. Opin. Lipidol.</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2011</infon><offset>31149</offset><text>Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2</text></passage><passage><infon key="fpage">1187</infon><infon key="lpage">1193</infon><infon key="name_0">surname:Civeira;given-names:F</infon><infon key="pub-id_doi">10.1016/j.amjcard.2008.06.056</infon><infon key="pub-id_pmid">18940289</infon><infon key="section_type">REF</infon><infon key="source">Am. J. Cardiol.</infon><infon key="type">ref</infon><infon key="volume">102</infon><infon key="year">2008</infon><offset>31252</offset><text>Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia</text></passage><passage><infon key="fpage">591</infon><infon key="lpage">597</infon><infon key="name_0">surname:Jarauta;given-names:E</infon><infon key="pub-id_doi">10.1016/j.numecd.2010.10.011</infon><infon key="pub-id_pmid">21196102</infon><infon key="section_type">REF</infon><infon key="source">Nutr. Metab. Cardiovasc. Dis.</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2012</infon><offset>31333</offset><text>Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia</text></passage><passage><infon key="fpage">295</infon><infon key="lpage">304</infon><infon key="name_0">surname:Grau;given-names:M</infon><infon key="pub-id_doi">10.1016/j.recesp.2010.11.005</infon><infon key="pub-id_pmid">21397375</infon><infon key="section_type">REF</infon><infon key="source">Rev. Esp. Cardiol.</infon><infon key="type">ref</infon><infon key="volume">64</infon><infon key="year">2011</infon><offset>31465</offset><text>Cardiovascular risk factors in Spain in the first decade of the 21st century, a pooled analysis with individual data from 11 population-based studies: The DARIOS Study</text></passage><passage><infon key="fpage">847</infon><infon key="lpage">55</infon><infon key="name_0">surname:GarcÃ­a-Esquinas;given-names:E</infon><infon key="pub-id_doi">10.1002/oby.21013</infon><infon key="pub-id_pmid">25683024</infon><infon key="section_type">REF</infon><infon key="source">Obesity (Silver Spring)</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2015</infon><offset>31633</offset><text>Obesity, fat distribution, and risk of frailty in two population-based cohorts of older adults in Spain</text></passage><passage><infon key="fpage">115</infon><infon key="lpage">28</infon><infon key="name_0">surname:Vazquez;given-names:G</infon><infon key="name_1">surname:Duval;given-names:S</infon><infon key="name_2">surname:Jacobs;given-names:DR</infon><infon key="name_3">surname:Silventoinen;given-names:K</infon><infon key="pub-id_doi">10.1093/epirev/mxm008</infon><infon key="pub-id_pmid">17494056</infon><infon key="section_type">REF</infon><infon key="source">Epidemiol. Rev.</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2007</infon><offset>31737</offset><text>Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis</text></passage></document>
</collection>